review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1084251994 |
P356 | DOI | 10.1186/S13054-017-1653-X |
P932 | PMC publication ID | 5376689 |
P698 | PubMed publication ID | 28366166 |
P50 | author | David M Maslove | Q59764657 |
P2093 | author name string | Daren K Heyland | |
John C Marshall | |||
Francois Lamontagne | |||
P2860 | cites work | A stepwise approach to justify phase III randomized clinical trials and enhance the likelihood of a positive result | Q46767352 |
Failure to Engage Hospitalized Elderly Patients and Their Families in Advance Care Planning | Q48268983 | ||
We should abandon randomized controlled trials in the intensive care unit | Q53078056 | ||
Individual gene expression and personalised medicine in sepsis. | Q54651494 | ||
InFACT: a global critical care research response to H1N1 | Q57237838 | ||
Will Precision Medicine Improve Population Health? | Q58400951 | ||
Genetic and environmental influences on premature death in adult adoptees | Q68278175 | ||
Personalized medicine, endotypes, and intensive care medicine | Q87170357 | ||
Precision Medicine for Critical Illness and Injury | Q88130274 | ||
Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) | Q26768292 | ||
G-DOC Plus - an integrative bioinformatics platform for precision medicine. | Q27319225 | ||
A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set | Q27325510 | ||
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels | Q28301776 | ||
The Translational Medicine Ontology and Knowledge Base: driving personalized medicine by bridging the gap between bench and bedside | Q28744215 | ||
MIMIC-III, a freely accessible critical care database | Q28871995 | ||
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
BioPortal: ontologies and integrated data resources at the click of a mouse | Q29617519 | ||
Precision medicine in cardiology | Q30249224 | ||
Identification of pediatric septic shock subclasses based on genome-wide expression profiling | Q30438982 | ||
Possible combinations of electronic data capture and randomization systems. principles and the realization with RANDI2 and OpenClinica | Q30754385 | ||
Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials | Q30826105 | ||
Fusing Randomized Trials With Big Data: The Key to Self-learning Health Care Systems? | Q30989624 | ||
Data Resource Profile: the Dutch National Intensive Care Evaluation (NICE) Registry of Admissions to Adult Intensive Care Units | Q31028868 | ||
Genetic influences on incidence and case-fatality of infectious disease | Q33586137 | ||
Informatics infrastructure for syndrome surveillance, decision support, reporting, and modeling of critical illness. | Q33744208 | ||
Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome | Q33750995 | ||
Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? | Q33946309 | ||
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. | Q34057044 | ||
Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma | Q34147463 | ||
Sepsis definitions: time for change | Q34649118 | ||
Heart rate variability in critical illness and critical care | Q34974165 | ||
PCSK9 is a critical regulator of the innate immune response and septic shock outcome. | Q35125516 | ||
Enrollment into a time sensitive clinical study in the critical care setting: results from computerized septic shock sniffer implementation | Q35200305 | ||
Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies | Q35672843 | ||
Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray. | Q36073104 | ||
A Survey of U.S Adults' Opinions about Conduct of a Nationwide Precision Medicine InitiativeĀ® Cohort Study of Genes and Environment | Q36105829 | ||
Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome | Q36166232 | ||
Continuous enteral and parenteral feeding each reduces heart rate variability but differentially influences monocyte gene expression in humans. | Q36191129 | ||
Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care | Q36272381 | ||
Development and implementation of a high-quality clinical database: the Australian and New Zealand Intensive Care Society Adult Patient Database | Q36504261 | ||
The microbiome and critical illness | Q36575777 | ||
Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study | Q36764754 | ||
Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients | Q36838630 | ||
Could Biomarkers Direct Therapy for the Septic Patient? | Q36852546 | ||
Toward precision medicine and health: Opportunities and challenges in allergic diseases | Q36916201 | ||
Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome | Q36925835 | ||
Identification of sepsis subtypes in critically ill adults using gene expression profiling | Q36928191 | ||
Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design | Q37213606 | ||
Metabolomic derangements are associated with mortality in critically ill adult patients | Q37534631 | ||
The Clinical Utility of Precision Medicine: Properly Assessing the Value of Emerging Diagnostic Tests | Q37809964 | ||
Sniffing out acute kidney injury in the ICU: do we have the tools? | Q38154109 | ||
The beginning of personalized medicine in sepsis: small steps to a bright future | Q38191987 | ||
Personalized medicine for ARDS: the 2035 research agenda | Q38381656 | ||
Brain Tissue Oxygenation in Patients with Septic Shock: a Feasibility Study | Q38387057 | ||
Sepsis: a roadmap for future research | Q38453261 | ||
The Evolving Landscape of HER2 Targeting in Breast Cancer | Q38552750 | ||
Precision respiratory medicine and the microbiome | Q38678093 | ||
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine | Q38862332 | ||
Why have clinical trials in sepsis failed? | Q39242451 | ||
Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children | Q39462634 | ||
Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. | Q39499760 | ||
Errors, Omissions, and Outliers in Hourly Vital Signs Measurements in Intensive Care | Q39504006 | ||
Genomics and pharmacogenomics of sepsis: so close and yet so far. | Q40623421 | ||
Combining Prognostic and Predictive Enrichment Strategies to Identify Children With Septic Shock Responsive to Corticosteroids. | Q40642645 | ||
Predicting Performance Status 1 Year After Critical Illness in Patients 80 Years or Older: Development of a Multivariable Clinical Prediction Model | Q40802479 | ||
Mortality in Multicenter Critical Care Trials: An Analysis of Interventions With a Significant Effect. | Q41141860 | ||
Septic shock in the era of precision medicine | Q41837623 | ||
"Big data" in the intensive care unit. Closing the data loop | Q42539340 | ||
Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis | Q44273818 | ||
Personalized medicine: genetic variation and loss of physiologic complexity are associated with mortality in 644 trauma patients | Q44540725 | ||
The randomized registry trial--the next disruptive technology in clinical research? | Q44663056 | ||
Thrombus aspiration during ST-segment elevation myocardial infarction | Q44802449 | ||
It's all in the genes: moving toward precision medicine in critical illness | Q45333854 | ||
The platform trial: an efficient strategy for evaluating multiple treatments. | Q45982371 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P921 | main subject | precision medicine | Q17075943 |
P304 | page(s) | 79 | |
P577 | publication date | 2017-04-03 | |
P1433 | published in | Critical Care | Q5186602 |
P1476 | title | A path to precision in the ICU. | |
P478 | volume | 21 |
Q64901793 | Critical Care, Critical Data. |
Q97530127 | Generalizable deep temporal models for predicting episodes of sudden hypotension in critically ill patients: a personalized approach |
Q92006074 | Impact of blood group on survival following critical illness: a single-centre retrospective observational study |
Q57067267 | Machine learning for real-time prediction of complications in critical care: a retrospective study |
Q61778761 | Paths into Sepsis: Trajectories of Presepsis Healthcare Use |
Q57158814 | Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids |
Q42346459 | Point-of-care ultrasonography: a practical step in the path to precision in critical care |
Q92736905 | Precision Medicine and its Role in the Treatment of Sepsis: A Personalised View |
Q59794487 | Predicting Patient-ventilator Asynchronies with Hidden Markov Models |
Q90614358 | Redefining postinjury fibrinolysis phenotypes using two viscoelastic assays |
Q42337552 | Systematic assessment of advanced respiratory physiology: precision medicine entering real-life ICU? |
Q47750410 | Therapeutic bronchoscopy vs. standard of care in acute respiratory failure: a systematic review |
Q47111588 | Time-sensitive therapeutics |
Q55341179 | Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study. |
Search more.